Oragenics and BRAINBox Partner to Advance Concussion Diagnosis and Treatment
Oragenics teams up with BRAINBox to develop a first-of-its-kind intranasal therapy for concussions.
Oragenics, Inc. has announced a strategic partnership with BRAINBox Solutions to develop an innovative "trigger-to-treat" platform for mild traumatic brain injuries (mTBI), commonly known as concussions. This collaboration integrates BRAINBox’s AI-driven diagnostic technology with Oragenics’ ONP-002, a novel intranasal therapeutic designed to reduce brain injury effects and promote recovery. Together, they aim to transform TBI care by enabling early detection, predictive prognosis, and targeted treatment.
“This partnership is a major step forward in concussion management,” said Janet Huffman, Interim CEO of Oragenics. “By combining BRAINBox’s diagnostic platform with our therapeutic candidate, we can improve patient outcomes and enhance clinical trial precision.” With over 5 million concussions occurring annually in the U.S., this collaboration could redefine concussion treatment, setting new standards for rapid intervention and personalized care.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
More from Pharma News
All stories →
Bristol-Myers Squibb Gains FDA Accelerated Approval for Iberdomide in Relapsed or Refractory Multiple Myeloma
Eton Pharmaceuticals Gains FDA Fast Track for AMGLIDIA and Targets 2027 NDA with ASN-001 Acquisition
Discussion